BridgeMD
New treatment option for Deep Infiltrating Endometriosis (DIE)
Official title Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
ClinicalTrials.gov ID: NCT07696351
What this study is testing
What is Triptorelin (GnRH agonists)?
Triptorelin (GnRH agonists) is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for deep infiltrating endometriosis (die).
Also referred to as GnRHa.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 39, women only
You may be able to join if
- Female patients aged 18 to 39 years.
- Diagnosed with deep infiltrating endometriosis by ultrasound at the study center.
- Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation.
- Having at least one good-quality frozen embryo.
- Willing to participate in this assigned by chance controlled study of GnRH-a pretreatment for deep infiltrating endometriosis and able to personally...
You likely can't join if
- Abnormal chromosomal karyotype.
- Other uterine diseases or conditions that may affect uterine cavity morphology or pregnancy outcomes, including intrauterine adhesions affecting the...
- Recurrent implantation failure.
- Contraindications to hormone replacement therapy or long-acting GnRH-a treatment.
- Osteoporosis or depressed mood.
- Currently participating in another clinical study.
See the full eligibility criteria
- Female patients aged 18 to 39 years.
- Diagnosed with deep infiltrating endometriosis by ultrasound at the study center.
- Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation.
- Having at least one good-quality frozen embryo.
- Willing to participate in this assigned by chance controlled study of GnRH-a pretreatment for deep infiltrating endometriosis and able to personally sign the written informed consent form.
- Abnormal chromosomal karyotype.
- Other uterine diseases or conditions that may affect uterine cavity morphology or pregnancy outcomes, including intrauterine adhesions affecting the uterine cavity, intramural uterine fibroids, moderate to severe...
- Recurrent implantation failure.
- Contraindications to hormone replacement therapy or long-acting GnRH-a treatment.
- Osteoporosis or depressed mood.
- Currently participating in another clinical study.
- Unable to adhere to study visits and follow-up, or planning to receive other treatment during the follow-up period.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 39 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.